Entinostat: A Promising Treatment Option for Refractory and Recurrent Ewing Sarcoma Patients
Biography Overview Test both in vitro and in vivo the efficacy of Entinostat in combination with i) current salvage chemotherapeutics for Ewing Sarcoma and ii) with the PARP inhibitor to identify a novel management approach for patients with refractory or recurrent Ewing Sarcoma.
Time
|